Our buying criteria for cat's claw are five short lines. This is the working behind them — including the one criterion we took OUT, and why. You do not need any of it to buy cat's claw. It is here because we would rather show it than ask you to take our word.
Whether you can find out what is actually in the bottle. On this plant that is harder than it sounds, because the same species grown at a different altitude produces a different set of compounds, and almost nobody measures which one they sold you.
An earlier draft of these rules told you to buy an extract standardized for one family of compounds and certified low in another — high in pentacyclic oxindole alkaloids, low in tetracyclic ones. We took it out. Not because it is wrong, but because we could not establish that it is right, and everyone who has argued either side of it sells something.
The claim that the tetracyclic compounds cancel out the pentacyclic ones comes from one line of laboratory work in the 1990s. The company behind it is Austrian, it holds four US patents from 1989 to 1998 on producing extracts with the tetracyclics removed, and its founder is a named author on the study. The work was done on cells in a dish and was never repeated in animals or in people. The same company's earlier patent had identified one of those tetracyclic compounds, isorhynchophylline, as stimulating immune function — the opposite of what the later claim needs it to do.
Because the standard reference reviews of this plant treat it as settled, and cite it without mentioning who paid for it. Meanwhile the people publishing the loudest objections sell whole-spectrum extracts that would look inferior if the claim held. So both sides of this argument have a product in the fight and nobody neutral has settled it. That is our actual finding, and it is why the criterion is gone rather than reversed. We are not going to tell you to pay more for a purified extract on evidence its own patent holder produced, and we are not going to tell you the science is fake when we cannot show that either.
The premium purified product is made from the ROOT. Cat's claw is a vine, and the harvest that lets it live is cutting the vine about a meter up so it grows back from the base. Taking the root kills the plant outright, which is why Peru's forestry authority would not issue permits for root extraction even while it remained legal. So the product sold on being the cleaner choice is the one made from the part whose harvest ends the plant. Peru's recorded exports went from 200 kilograms in 1993 to 726,684 kilograms in 1995 in two years, which is the pressure that made any of this matter.
We checked eleven cat's claw products sold in the US in August 2026. Eight name the species. Only four say which part of the plant is in the bottle — three inner bark, one root. Three publish any alkaloid figure at all, and one of those three is the only brand that publishes the split rather than a single total: 3 percent total, of which 2.73 pentacyclic and 0.27 tetracyclic. NOT ONE of the eleven publishes a certificate you can open against a batch. Zero out of eleven, the same score as coconut oil.
Cat's claw is routinely bulked out with Uncaria guianensis, a related vine that is not the same plant. We could find no published figure for how often US products are the wrong species, so we are not going to invent one. But the substitution is well enough documented that a brand naming the species is telling you something, and a brand that just says cat's claw bark is not. There is also a quieter reason to want it: it is a plausible explanation for why some products test high in the tetracyclic compounds in the first place — not a different chemistry, a different plant.
The pregnancy caution. Cat's claw was used as a contraceptive by the Ashaninka people of the Peruvian Amazon, who boiled several kilograms of root down to about a cup and drank it daily during menstruation for three months. This is not folklore we are repeating loosely: the founder of the company above filed a patent in 1982, a decade before the commercial argument started, titled for a cytostatic, contraceptive and anti-inflammatory agent from Uncaria tomentosa roots. Two parties with nothing in common describe the same use of the same part of the same plant. That is why the caution on the page is flat rather than hedged.
Because the buying section is how we chose, not homework for you. The page says to want the species named, to want the inner bark, to want no hidden fillers, to want it harvested in a way the vine survives, and to want it tested. This is what we do when we apply that — and it is where a rule goes when we decide we cannot stand behind it.
We have no product of our own and take no payment for a place on a list. Where a figure below is not ours, the source is named so you can check it yourself.